Folgen
Raphael M. Bonelli
Raphael M. Bonelli
Associate Professor of Psychiatry, Sigmund Freud University Vienna
Bestätigte E-Mail-Adresse bei sfu.ac.at - Startseite
Titel
Zitiert von
Zitiert von
Jahr
Mental disorders, religion and spirituality 1990 to 2010: a systematic evidence-based review
RM Bonelli, HG Koenig
Journal of religion and health 52, 657-673, 2013
7762013
Frontal-subcortical circuitry and behavior
RM Bonelli, JL Cummings
Dialogues in clinical neuroscience 9 (2), 141-151, 2007
7682007
CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion
JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ...
Neurology 78 (10), 690-695, 2012
4182012
Religious and spiritual factors in depression: review and integration of the research
R Bonelli, RE Dew, HG Koenig, DH Rosmarin, S Vasegh
Depression research and treatment 2012, 2012
3302012
Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY)
E van Duijn, D Craufurd, AAM Hubers, EJ Giltay, R Bonelli, H Rickards, ...
Journal of Neurology, Neurosurgery & Psychiatry 85 (12), 1411-1418, 2014
3022014
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
DJH Moss, AF Pardiñas, D Langbehn, K Lo, BR Leavitt, R Roos, A Durr, ...
The Lancet Neurology 16 (9), 701-711, 2017
2862017
Pharmacological management of Huntington's disease: an evidence-based review
RM Bonelli, GK Wenning
Current pharmaceutical design 12 (21), 2701-2720, 2006
2072006
An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels
J De Leon, G Schoretsanitis, RL Smith, E Molden, A Solismaa, N Seppälä, ...
Pharmacopsychiatry 55 (02), 73-86, 2022
1622022
Neuroprotection in Huntington's disease: a 2-year study on minocycline
RM Bonelli, AK Hödl, P Hofmann, HP Kapfhammer
International clinical psychopharmacology 19 (6), 337-342, 2004
1512004
Psychotherapie und Spiritualität
M Utsch, RM Bonelli, S Pfeifer
Springer Berlin Heidelberg, 2014
1442014
A systematic review of the treatment studies in Huntington’s disease since 1990
RM Bonelli, P Hofmann
Expert opinion on pharmacotherapy 8 (2), 141-153, 2007
1412007
Frontal-subcortical dementias
RM Bonelli, JL Cummings
The neurologist 14 (2), 100-107, 2008
1352008
Sexuality in multiple sclerosis
EZ Schmidt, P Hofmann, G Niederwieser, HP Kapfhammer, RM Bonelli
Journal of Neural Transmission 112, 1201-1211, 2005
1302005
Huntington's disease: present treatments and future therapeutic modalities
RM Bonelli, GK Wenning, HP Kapfhammer
International clinical psychopharmacology 19 (2), 51-62, 2004
1222004
Prevalence of autoimmune thyroiditis and non-immune thyroid disease in multiple sclerosis
G Niederwieser, W Buchinger, RM Bonelli, A Berghold, F Reisecker, ...
Journal of neurology 250, 672-675, 2003
1092003
Minocycline for Huntington’s disease: an open label study
RM Bonelli, C Heuberger, F Reisecker
Neurology 60 (5), 883-884, 2003
1072003
Olanzapine for Huntington's disease: an open label study
RM Bonelli, FA Mahnert, G Niederwieser
Clinical neuropharmacology 25 (5), 263-265, 2002
952002
Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study
R Reilmann, A McGarry, ID Grachev, JM Savola, B Borowsky, E Eyal, ...
The Lancet Neurology 18 (2), 165-176, 2019
942019
Strukturelles Neuroimaging der Basalganglien bei Schizophrenie: ein Review
GN Brandt, RM Bonelli
Wiener Medizinische Wochenschrift 158, 84-90, 2008
852008
Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR
AK Holl, L Wilkinson, A Painold, EM Holl, RM Bonelli
International clinical psychopharmacology 25 (1), 46-50, 2010
832010
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20